On February 17, 2026, Perceptive Advisors disclosed the purchase of 978,662 shares of Apogee Therapeutics (NASDAQ:APGE), with an estimated transaction value of $61.64 million based on the fourth-quarter average share price. This increased their total holdings to 2,330,651 shares, with a position value rise of $122.20 million due to new acquisitions and share price appreciation. Apogee Therapeutics specializes in developing extended half-life monoclonal antibodies for treating atopic dermatitis and chronic obstructive pulmonary disease. The company aims to advance its clinical programs to commercialization, targeting significant unmet needs in immunology.
Want More Context? 🔎
Loading PerspectiveSplit analysis...
